Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 26, 2026

Large Language Model Market Forecasted to Reach USD 149.89 Billion by 2035 Driven by AI Automation and Open-Source Adoption

View original at globenewswire.com
Large Language Model Market Forecasted to Reach USD 149.89 Billion by 2035 Driven by AI Automation and Open-Source Adoption Ottawa, Feb…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The customer service segment is anticipated to register the fastest CAGR during the forecast period

    80% confidence

  • The healthcare segment held a significant share in 2025, while the finance segment is projected to expand at a rapid pace

    80% confidence

  • The cloud segment is expected to grow at the highest rate throughout the study period

    80% confidence

  • Chatbots and virtual assistants dominated the market with a 28% share in 2025

    80% confidence

  • Asia Pacific is expected to witness the highest growth rate over the forecast period

    80% confidence

  • Growing automation across various tasks and strong focus on accelerating decision-making increase demand for LLM

    80% confidence

  • The global large language model market will grow from USD 10.57 billion in 2026 to nearly USD 149.89 billion by 2035, expanding at a CAGR of 34.44% from 2026 to 2035

    80% confidence

  • North America led the global large language model market in 2025, capturing a 33% revenue share

    80% confidence

  • The U.S. large language model market size is expected to cross around USD 37.98 billion by 2035, increasing from USD 2.62 billion in 2026, growing at a CAGR of 34.78% from 2026 to 2035

    80% confidence

  • The on-premises segment accounted for a major 59% share in 2025

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com